Biodyne Q1 2026: Net Profit Turns Positive, Operating Loss Continues

Consolidated Q1 2026 revenue: KRW 867M (down 5.4% YoY), operating loss: KRW 403M
Net profit: KRW 155M (vs net loss of KRW 435M in Q1 2025) due to financial income (FX gains, etc.)
Transferred KRW 20B from capital surplus to retained earnings to cover deficit; total equity: KRW 44.3B
Cash and equivalents: KRW 12.2B, zero debt, sound financial structure
Royalty and milestone (USD 6.75M) income from Roche technology license agreement ongoing
Self-collection cytology device 'Earlypap' patents registered; preparing for domestic and global launch